Real-World Survey Quantifies Patient Satisfaction With Hizentra

Real-world survey data show that patients receiving Hizentra were highly satisfied with treatment.
Real-world survey data show that patients receiving Hizentra were highly satisfied with treatment.

This article is part of Pulmonology Advisor's coverage of the American Academy of Allergy, Asthma & Immunology, taking place in Orlando, Florida. Our staff will report on medical research related to asthma and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI/WAO 2018.


Patients treated with Hizentra, a 20% subcutaneous immunoglobulin, were highly satisfied with treatment, according to real-world survey data presented at the 2018 Joint Congress of the American Academy of Allergy, Asthma & Immunology and World Allergy Organization (AAAAI/WAO), held March 2-5, 2018, in Orlando, Florida.

Jacob M. Romano, PharmD, and Rajiv Mallick, PhD, from CSL Behring in King of Prussia, Pennsylvania, administered an online survey between March 10 and March 31, 2017, to determine whether patients with primary immunodeficiency were satisfied with Hizentra treatment. The survey was completed by patients and caregivers of pediatric patients with primary immunodeficiency who were receiving immunoglobulin therapy.

The investigators examined Treatment Satisfaction Questionnaire for Medication (TSQM) scores for patients receiving Hizentra, which were measured on a scale from 0 (poorest satisfaction) to 100 (perfect satisfaction). Desirable thresholds for treatment satisfaction were 67 for effectiveness, 75 for adverse effects, 67 for convenience, 67 for global satisfaction, and 69 for total TSQM scores.

Related Articles

A total of 247 patients receiving Hizentra completed the TSQM. The mean scores were 73 for effectiveness, 83 for adverse effects, 72 for convenience, 80 for global satisfaction, and 76 for total TSQM score. In addition, the percentage of participants whose scores were above the desired thresholds were 72% for the total TSQM score, 74% for effectiveness, 73% for adverse effects, 68% for convenience, and 85% for global satisfaction.

The researchers noted that no significant differences were observed when the scores were stratified by primary treatment decision maker.

Visit Pulmonology Advisor's conference section for continuous coverage from AAAAI/WAO 2018


Reference

Romano JM, Mallick R. High treatment satisfaction with Hizentra, a 20% subcutaneous immunoglobulin (SCIG): real-world survey data. Presented at the 2018 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress; March 2-5, 2018; Orlando, FL. Abstract 844.